Analysis of major trials including SELECT, STEP-HFpEF, and SURMOUNT-5 reveals that GLP-1 receptor agonists and dual GIP/GLP-1 agonists deliver cardiovascular protection that exceeds what weight loss alone would predict. These medications reduced major adverse cardiovascular events while improving functional capacity, lowering blood pressure, triglycerides, and inflammatory marker C-reactive protein. The cardiovascular benefits represent a paradigm shift in understanding obesity pharmacotherapy. Rather than simple weight-loss tools, these agents appear to directly modulate metabolic and inflammatory pathways independent of fat reduction. This finding has profound implications for clinical practice, suggesting obese patients with cardiovascular risk factors might benefit from these medications even if weight loss plateaus or is modest. The research challenges the traditional view that obesity drugs work solely through caloric restriction and fat loss. However, the specific mechanisms underlying these pleiotropic effects remain unclear, and long-term safety data beyond current trial periods is still needed. This represents confirmatory evidence building on emerging cardiovascular outcome data, solidifying GLP-1 agonists as metabolic modulators rather than mere appetite suppressants.